Panel of experts discuss survivorship challenges and potential areas for study.

by Marci A. Landsmann

At the AACR Annual Meeting 2018, researchers at Google compared the speed and accuracy of human pathologists and computer algorithms in diagnosing and grading cancer.

by Kevin McLaughlin

A trio of clinical trials at the AACR Annual Meeting spotlight new avenues for non-small cell lung cancer treatment.

by Brad Jones

At the AACR Annual Meeting, researchers and regulators discuss what it means to tie approval of an immunotherapy to tumors' molecular characteristics, not to their tissues of origin.

by Kate Yandell

Cancer researchers and patient advocates spoke about progress against cancer at a public education forum sponsored by the American Association for Cancer Research.

by Kevin McLaughlin

In a phase III clinical trial, pembrolizumab yielded a 75.4 percent recurrence-free survival rate after 12 months among patients whose stage III melanoma tumors had been fully resected.

by Brad Jones

AACR’s Scientist↔Survivor Program marks a milestone as patient advocates continue to shape research and policy.

by Marci A. Landsmann

Two graduates of the AACR Scientist↔Survivor Program share tips for getting the most out of large scientific conferences.

by Bob Riter and Carole Baas

In a sea of p-values and distribution curves, patient advocates and survivors at a scientific gathering remind researchers who is behind the numbers.

by Marci A. Landsmann

Researchers are combining immunotherapies with each other and with other treatments in hopes that a larger proportion of patients will have long-term benefits.

by Kate Yandell